AstraZeneca Tagrisso recommended for approval in EU by CHMP for patients with unresectable EGFR mutated lung cancer Ruchika Sharma19 Nov 2024 12:15 PM ISTCambridge: AstraZeneca's Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients...
AstraZeneca invests USD 3.5 billion in RnD, manufacturing in US Ruchika Sharma15 Nov 2024 3:08 PM ISTCambridge: AstraZeneca has announced $3.5 billion of capital investment in the United States focused on expanding the Company's research and...
AstraZeneca, Daiichi Sankyo submits Datopotamab deruxtecan new BLA for accelerated approval in US for lung cancer Ruchika Sharma14 Nov 2024 3:15 PM ISTAstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab deruxtecan...
CDSCO panel Approves AstraZeneca's Protocol Amendment proposal for Datopotamab Deruxtecan study Dr. Divya Colin7 Nov 2024 6:15 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved AstraZeneca's...
AstraZeneca Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis Ruchika Sharma31 Oct 2024 1:45 PM ISTCambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult...
Roche seeks to block Novo Nordisk's Catalent deal over weight-loss drug competition MD Bureau24 Oct 2024 2:09 PM IST"Limiting the competition in this space is not a good idea," Thomas Schinecker, CEO, Roche said.
Merck's RSV antibody Clesrovimab for infants shows 60.4% effectiveness in mid-to-late stage clinical trial MD Bureau19 Oct 2024 12:15 PM ISTThe drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.
Block Novo Holdings' USD16.5B Catalent acquisition: Consumer Groups Urge FTC over antitrust concerns MD Bureau19 Oct 2024 11:30 AM ISTThe deal could constrain options for competitors such as Amgen, Pfizer, Roche, and AstraZeneca , who are reportedly developing their own GLP 1 drugs.
Medical Bulletin 07/ October/ 2024 Dr. Bhumika Maikhuri7 Oct 2024 3:00 PM ISTHere are the top medical news for the day:Want to Prevent Back Pain? Reduce Sitting TimeA new study from the University of Turku in Finland showed...
WHO recommends maternal vaccine and antibody shot for preventing RSV in infants Dr. Bhumika Maikhuri7 Oct 2024 8:45 AM ISTThe World Health Organization recommended vaccinating pregnant women and administering infants with an antibody to prevent severe respiratory synctial...
Astrazeneca Calquence granted priority review by USFDA for previously untreated mantle cell lymphoma Ruchika Sharma5 Oct 2024 2:30 PM ISTCambridge: AstraZeneca's supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted and granted Priority Review in...
USFDA grants priority review to AstraZeneca-Daiichi Sankyo Enhertu for HER2-low, HER2 Ultralow Breast Cancer Ruchika Sharma3 Oct 2024 9:15 AM ISTAstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and...
